InvAscent looks to exit Aizant Drug at $350-400 mn valuation

The investment firm has approached PE funds to buy a controlling stake in the drug development company

Disclaimer : Mytimesnow (MTN) lets you explore worldwide viral news just by analyzing social media trends. Tap read more at source for full news. The inclusion of any links does not necessarily imply any endorsement of the views expressed within them.